Last reviewed · How we verify
Kisspeptin 112-121
At a glance
| Generic name | Kisspeptin 112-121 |
|---|---|
| Also known as | metastin 45-54, Metastin 45-54 |
| Sponsor | Stephanie B. Seminara, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease (PHASE1)
- Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test (PHASE1)
- Recall by Genotype: Neuropeptide Stimulation (PHASE1)
- Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism (PHASE2)
- Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea (PHASE2)
- Dampening the Reproductive Axis With Continuous Kisspeptin (PHASE1)
- Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders (PHASE1)
- Kisspeptin Administration Subcutaneously to Patients With IHH (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kisspeptin 112-121 CI brief — competitive landscape report
- Kisspeptin 112-121 updates RSS · CI watch RSS
- Stephanie B. Seminara, MD portfolio CI